カテゴリー： 世界, 医療/バイオ, LP Information

世界の再集合体鳥インフルエンザウイルスワクチン市場予測 2023年-2029年

【英語タイトル】Global Reassortant Avian Influenza Virus Vaccine Market Growth 2023-2029

LP Informationが出版した調査資料（LP23DC02948）・商品コード：LP23DC02948
・発行会社（調査会社）：LP Information
・発行日：2023年11月
・ページ数：111
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後2-3営業日）
・調査対象地域：グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
・産業分野：医薬品＆医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,660 ⇒換算￥556,320見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,490 ⇒換算￥834,480見積依頼/購入/質問フォーム
Corporate User（閲覧人数制限なし）USD7,320 ⇒換算￥1,112,640見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

LPインフォメーションの最新刊調査レポート「世界の再集合体鳥インフルエンザウイルスワクチン市場」は、過去の販売実績から2022年の世界の再集合体鳥インフルエンザウイルスワクチンの総販売量を検討し、2023年から2029年の予測される再集合体鳥インフルエンザウイルスワクチンの販売量を地域別・市場分野別に包括的に分析しています。本調査レポートでは、地域別、市場分野別、サブセクター別の再集合体鳥インフルエンザウイルスワクチンの市場規模を掲載し、XXX百万米ドル規模の世界の再集合体鳥インフルエンザウイルスワクチン市場の詳細な分析を提供します。本インサイトレポートは、世界の再集合体鳥インフルエンザウイルスワクチン業界を包括的に分析し、製品セグメント、企業情報、売上、市場シェア、最新動向、M&A活動に関する主要トレンドを明らかにしています。
また、本レポートでは、加速する世界の再集合体鳥インフルエンザウイルスワクチン市場における各社の独自のポジションをより深く理解するために、再集合体鳥インフルエンザウイルスワクチン製品ポートフォリオ、能力、市場参入戦略、市場でのポジション、海外展開に焦点を当て、主要なグローバル企業の戦略を分析しています。

世界の再集合体鳥インフルエンザウイルスワクチン市場規模は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに成長すると予測され、2023年から2029年までの年平均成長率は000%と予測されます。再集合体鳥インフルエンザウイルスワクチンの米国市場は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加し、2023年から2029年までのCAGRは000％と予測されています。再集合体鳥インフルエンザウイルスワクチンの中国市場は、2023年から2029年までの年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されます。再集合体鳥インフルエンザウイルスワクチンのヨーロッパ市場は、2023年から2029年にかけて年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されています。

再集合体鳥インフルエンザウイルスワクチンの世界主要メーカーとしては、Zoetis、 Boehringer-Ingelheim、 Eurovet、 Merck Animal Health、 BICR、 China Animal Husbandry Industry、 Weike Biotechnology、 Ringpu、 Guangdong Winsun Bio Pharmaceutical、 Pulike、 QYH Biotech、 YEBIO Bioengineering、 Yikang Biological、 DAHUANONG、 Guangzhou South China Biological Medicineなどを掲載しており、売上の面では、世界の2大企業が2022年にほぼ000％のシェアを占めています。

本レポートでは、製品タイプ、用途、主要メーカー、主要地域、国別の再集合体鳥インフルエンザウイルスワクチン市場の包括的な概要、市場シェア、成長機会などの情報を提供しています。

【市場細分化】

この調査では再集合体鳥インフルエンザウイルスワクチン市場をセグメンテーションし、種類別 (二価不活化ワクチン、三価不活化ワクチン)、用途別 (子豚、成豚)、および地域別 (アジア太平洋、南北アメリカ、ヨーロッパ、および中東・アフリカ) の市場規模を予測しています。

・種類別区分：二価不活化ワクチン、三価不活化ワクチン

・用途別区分：子豚、成豚

・地域別区分
南北アメリカ（アメリカ、カナダ、メキシコ、ブラジル）
アジア太平洋（中国、日本、韓国、東南アジア、インド、オーストラリア）
ヨーロッパ（ドイツ、フランス、イギリス、イタリア、ロシア）
中東・アフリカ（エジプト、南アフリカ、イスラエル、トルコ、GCC諸国）

【本レポートで扱う主な質問】

・世界の再集合体鳥インフルエンザウイルスワクチン市場の10年間の市場状況・展望は？
・世界および地域別に見た再集合体鳥インフルエンザウイルスワクチン市場成長の要因は何か？
・再集合体鳥インフルエンザウイルスワクチンの市場機会はエンドマーケットの規模によってどのように変化するのか？
・再集合体鳥インフルエンザウイルスワクチンのタイプ別、用途別の内訳は？
・新型コロナウイルス感染症とロシア・ウクライナ戦争の影響は？

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要：再集合体鳥インフルエンザウイルスワクチンの年間販売量2018-2029、地域別現状・将来分析
・再集合体鳥インフルエンザウイルスワクチンの種類別セグメント：二価不活化ワクチン、三価不活化ワクチン
・再集合体鳥インフルエンザウイルスワクチンの種類別販売量：2018-2023年の販売量、売上、市場シェア、販売価格
・再集合体鳥インフルエンザウイルスワクチンの用途別セグメント：子豚、成豚
・再集合体鳥インフルエンザウイルスワクチンの用途別販売量：2018-2023年の販売量、売上、市場シェア、販売価格

企業別世界の再集合体鳥インフルエンザウイルスワクチン市場
・企業別のグローバル再集合体鳥インフルエンザウイルスワクチン市場データ：2018-2023年の年間販売量、市場シェア
・企業別の再集合体鳥インフルエンザウイルスワクチンの年間売上：2018-2023年の売上、市場シェア
・企業別の再集合体鳥インフルエンザウイルスワクチン販売価格
・主要企業の再集合体鳥インフルエンザウイルスワクチン生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

再集合体鳥インフルエンザウイルスワクチンの地域別レビュー
・地域別の再集合体鳥インフルエンザウイルスワクチン市場規模2018-2023：年間販売量、売上
・主要国別の再集合体鳥インフルエンザウイルスワクチン市場規模2018-2023：年間販売量、売上
・南北アメリカの再集合体鳥インフルエンザウイルスワクチン販売の成長
・アジア太平洋の再集合体鳥インフルエンザウイルスワクチン販売の成長
・ヨーロッパの再集合体鳥インフルエンザウイルスワクチン販売の成長
・中東・アフリカの再集合体鳥インフルエンザウイルスワクチン販売の成長

南北アメリカ市場
・南北アメリカの国別の再集合体鳥インフルエンザウイルスワクチン販売量、売上（2018-2023）
・南北アメリカの再集合体鳥インフルエンザウイルスワクチンの種類別販売量
・南北アメリカの再集合体鳥インフルエンザウイルスワクチンの用途別販売量
・アメリカ市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋市場
・アジア太平洋の国別の再集合体鳥インフルエンザウイルスワクチン販売量、売上（2018-2023）
・アジア太平洋の再集合体鳥インフルエンザウイルスワクチンの種類別販売量
・アジア太平洋の再集合体鳥インフルエンザウイルスワクチンの用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

ヨーロッパ市場
・ヨーロッパの国別の再集合体鳥インフルエンザウイルスワクチン販売量、売上（2018-2023）
・ヨーロッパの再集合体鳥インフルエンザウイルスワクチンの種類別販売量
・ヨーロッパの再集合体鳥インフルエンザウイルスワクチンの用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別の再集合体鳥インフルエンザウイルスワクチン販売量、売上（2018-2023）
・中東・アフリカの再集合体鳥インフルエンザウイルスワクチンの種類別販売量
・中東・アフリカの再集合体鳥インフルエンザウイルスワクチンの用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・再集合体鳥インフルエンザウイルスワクチンの製造コスト構造分析
・再集合体鳥インフルエンザウイルスワクチンの製造プロセス分析
・再集合体鳥インフルエンザウイルスワクチンの産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル：直接販売チャンネル、間接販売チャンネル
・再集合体鳥インフルエンザウイルスワクチンの主要なグローバル販売業者
・再集合体鳥インフルエンザウイルスワクチンの主要なグローバル顧客

地域別の再集合体鳥インフルエンザウイルスワクチン市場予測レビュー
・地域別の再集合体鳥インフルエンザウイルスワクチン市場規模予測（2024-2029）
・南北アメリカの国別予測
・アジア太平洋の国別予測
・ヨーロッパの国別予測
・再集合体鳥インフルエンザウイルスワクチンの種類別市場規模予測
・再集合体鳥インフルエンザウイルスワクチンの用途別市場規模予測

主要企業分析
Zoetis、 Boehringer-Ingelheim、 Eurovet、 Merck Animal Health、 BICR、 China Animal Husbandry Industry、 Weike Biotechnology、 Ringpu、 Guangdong Winsun Bio Pharmaceutical、 Pulike、 QYH Biotech、 YEBIO Bioengineering、 Yikang Biological、 DAHUANONG、 Guangzhou South China Biological Medicine
・企業情報
・再集合体鳥インフルエンザウイルスワクチン製品
・再集合体鳥インフルエンザウイルスワクチン販売量、売上、価格、粗利益（2018-2023）
・主要ビジネス概要
・最新動向

調査結果および結論

The global Reassortant Avian Influenza Virus Vaccine market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Reassortant Avian Influenza Virus Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Reassortant Avian Influenza Virus Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Reassortant Avian Influenza Virus Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Reassortant Avian Influenza Virus Vaccine players cover Zoetis, Boehringer-Ingelheim, Eurovet, Merck Animal Health, BICR, China Animal Husbandry Industry, Weike Biotechnology, Ringpu and Guangdong Winsun Bio Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Recombinant avian influenza virus (H5+H7) inactivated vaccine is suitable for a variety of target animals, including breeder hens, layer hens, broiler chickens, breeder ducks, geese, etc. According to the immunization schedule, the primary immunization of chicks, ducklings and goslings lasts The period is 2 months, and it can be used for emergency immunization against highly pathogenic avian influenza at the same time.
LPI (LP Information)’ newest research report, the “Reassortant Avian Influenza Virus Vaccine Industry Forecast” looks at past sales and reviews total world Reassortant Avian Influenza Virus Vaccine sales in 2022, providing a comprehensive analysis by region and market sector of projected Reassortant Avian Influenza Virus Vaccine sales for 2023 through 2029. With Reassortant Avian Influenza Virus Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Reassortant Avian Influenza Virus Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Reassortant Avian Influenza Virus Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Reassortant Avian Influenza Virus Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Reassortant Avian Influenza Virus Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Reassortant Avian Influenza Virus Vaccine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Reassortant Avian Influenza Virus Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Reassortant Avian Influenza Virus Vaccine market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Bivalent Inactivated Vaccine
Trivalent Inactivated Vaccine
Segmentation by application
Piglets
Adults Pigs
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company’s coverage, product portfolio, its market penetration.
Zoetis
Boehringer-Ingelheim
Eurovet
Merck Animal Health
BICR
China Animal Husbandry Industry
Weike Biotechnology
Ringpu
Guangdong Winsun Bio Pharmaceutical
Pulike
QYH Biotech
YEBIO Bioengineering
Yikang Biological
DAHUANONG
Guangzhou South China Biological Medicine
Key Questions Addressed in this Report
What is the 10-year outlook for the global Reassortant Avian Influenza Virus Vaccine market?
What factors are driving Reassortant Avian Influenza Virus Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Reassortant Avian Influenza Virus Vaccine market opportunities vary by end market size?
How does Reassortant Avian Influenza Virus Vaccine break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

❖ レポートの目次 ❖

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Reassortant Avian Influenza Virus Vaccine Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Reassortant Avian Influenza Virus Vaccine by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Reassortant Avian Influenza Virus Vaccine by Country/Region, 2018, 2022 & 2029
2.2 Reassortant Avian Influenza Virus Vaccine Segment by Type
2.2.1 Bivalent Inactivated Vaccine
2.2.2 Trivalent Inactivated Vaccine
2.3 Reassortant Avian Influenza Virus Vaccine Sales by Type
2.3.1 Global Reassortant Avian Influenza Virus Vaccine Sales Market Share by Type (2018-2023)
2.3.2 Global Reassortant Avian Influenza Virus Vaccine Revenue and Market Share by Type (2018-2023)
2.3.3 Global Reassortant Avian Influenza Virus Vaccine Sale Price by Type (2018-2023)
2.4 Reassortant Avian Influenza Virus Vaccine Segment by Application
2.4.1 Piglets
2.4.2 Adults Pigs
2.5 Reassortant Avian Influenza Virus Vaccine Sales by Application
2.5.1 Global Reassortant Avian Influenza Virus Vaccine Sale Market Share by Application (2018-2023)
2.5.2 Global Reassortant Avian Influenza Virus Vaccine Revenue and Market Share by Application (2018-2023)
2.5.3 Global Reassortant Avian Influenza Virus Vaccine Sale Price by Application (2018-2023)
3 Global Reassortant Avian Influenza Virus Vaccine by Company
3.1 Global Reassortant Avian Influenza Virus Vaccine Breakdown Data by Company
3.1.1 Global Reassortant Avian Influenza Virus Vaccine Annual Sales by Company (2018-2023)
3.1.2 Global Reassortant Avian Influenza Virus Vaccine Sales Market Share by Company (2018-2023)
3.2 Global Reassortant Avian Influenza Virus Vaccine Annual Revenue by Company (2018-2023)
3.2.1 Global Reassortant Avian Influenza Virus Vaccine Revenue by Company (2018-2023)
3.2.2 Global Reassortant Avian Influenza Virus Vaccine Revenue Market Share by Company (2018-2023)
3.3 Global Reassortant Avian Influenza Virus Vaccine Sale Price by Company
3.4 Key Manufacturers Reassortant Avian Influenza Virus Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Reassortant Avian Influenza Virus Vaccine Product Location Distribution
3.4.2 Players Reassortant Avian Influenza Virus Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Reassortant Avian Influenza Virus Vaccine by Geographic Region
4.1 World Historic Reassortant Avian Influenza Virus Vaccine Market Size by Geographic Region (2018-2023)
4.1.1 Global Reassortant Avian Influenza Virus Vaccine Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Reassortant Avian Influenza Virus Vaccine Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Reassortant Avian Influenza Virus Vaccine Market Size by Country/Region (2018-2023)
4.2.1 Global Reassortant Avian Influenza Virus Vaccine Annual Sales by Country/Region (2018-2023)
4.2.2 Global Reassortant Avian Influenza Virus Vaccine Annual Revenue by Country/Region (2018-2023)
4.3 Americas Reassortant Avian Influenza Virus Vaccine Sales Growth
4.4 APAC Reassortant Avian Influenza Virus Vaccine Sales Growth
4.5 Europe Reassortant Avian Influenza Virus Vaccine Sales Growth
4.6 Middle East & Africa Reassortant Avian Influenza Virus Vaccine Sales Growth
5 Americas
5.1 Americas Reassortant Avian Influenza Virus Vaccine Sales by Country
5.1.1 Americas Reassortant Avian Influenza Virus Vaccine Sales by Country (2018-2023)
5.1.2 Americas Reassortant Avian Influenza Virus Vaccine Revenue by Country (2018-2023)
5.2 Americas Reassortant Avian Influenza Virus Vaccine Sales by Type
5.3 Americas Reassortant Avian Influenza Virus Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Reassortant Avian Influenza Virus Vaccine Sales by Region
6.1.1 APAC Reassortant Avian Influenza Virus Vaccine Sales by Region (2018-2023)
6.1.2 APAC Reassortant Avian Influenza Virus Vaccine Revenue by Region (2018-2023)
6.2 APAC Reassortant Avian Influenza Virus Vaccine Sales by Type
6.3 APAC Reassortant Avian Influenza Virus Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Reassortant Avian Influenza Virus Vaccine by Country
7.1.1 Europe Reassortant Avian Influenza Virus Vaccine Sales by Country (2018-2023)
7.1.2 Europe Reassortant Avian Influenza Virus Vaccine Revenue by Country (2018-2023)
7.2 Europe Reassortant Avian Influenza Virus Vaccine Sales by Type
7.3 Europe Reassortant Avian Influenza Virus Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Reassortant Avian Influenza Virus Vaccine by Country
8.1.1 Middle East & Africa Reassortant Avian Influenza Virus Vaccine Sales by Country (2018-2023)
8.1.2 Middle East & Africa Reassortant Avian Influenza Virus Vaccine Revenue by Country (2018-2023)
8.2 Middle East & Africa Reassortant Avian Influenza Virus Vaccine Sales by Type
8.3 Middle East & Africa Reassortant Avian Influenza Virus Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Reassortant Avian Influenza Virus Vaccine
10.3 Manufacturing Process Analysis of Reassortant Avian Influenza Virus Vaccine
10.4 Industry Chain Structure of Reassortant Avian Influenza Virus Vaccine
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Reassortant Avian Influenza Virus Vaccine Distributors
11.3 Reassortant Avian Influenza Virus Vaccine Customer
12 World Forecast Review for Reassortant Avian Influenza Virus Vaccine by Geographic Region
12.1 Global Reassortant Avian Influenza Virus Vaccine Market Size Forecast by Region
12.1.1 Global Reassortant Avian Influenza Virus Vaccine Forecast by Region (2024-2029)
12.1.2 Global Reassortant Avian Influenza Virus Vaccine Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Reassortant Avian Influenza Virus Vaccine Forecast by Type
12.7 Global Reassortant Avian Influenza Virus Vaccine Forecast by Application
13 Key Players Analysis
13.1 Zoetis
13.1.1 Zoetis Company Information
13.1.2 Zoetis Reassortant Avian Influenza Virus Vaccine Product Portfolios and Specifications
13.1.3 Zoetis Reassortant Avian Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Zoetis Main Business Overview
13.1.5 Zoetis Latest Developments
13.2 Boehringer-Ingelheim
13.2.1 Boehringer-Ingelheim Company Information
13.2.2 Boehringer-Ingelheim Reassortant Avian Influenza Virus Vaccine Product Portfolios and Specifications
13.2.3 Boehringer-Ingelheim Reassortant Avian Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Boehringer-Ingelheim Main Business Overview
13.2.5 Boehringer-Ingelheim Latest Developments
13.3 Eurovet
13.3.1 Eurovet Company Information
13.3.2 Eurovet Reassortant Avian Influenza Virus Vaccine Product Portfolios and Specifications
13.3.3 Eurovet Reassortant Avian Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Eurovet Main Business Overview
13.3.5 Eurovet Latest Developments
13.4 Merck Animal Health
13.4.1 Merck Animal Health Company Information
13.4.2 Merck Animal Health Reassortant Avian Influenza Virus Vaccine Product Portfolios and Specifications
13.4.3 Merck Animal Health Reassortant Avian Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Merck Animal Health Main Business Overview
13.4.5 Merck Animal Health Latest Developments
13.5 BICR
13.5.1 BICR Company Information
13.5.2 BICR Reassortant Avian Influenza Virus Vaccine Product Portfolios and Specifications
13.5.3 BICR Reassortant Avian Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 BICR Main Business Overview
13.5.5 BICR Latest Developments
13.6 China Animal Husbandry Industry
13.6.1 China Animal Husbandry Industry Company Information
13.6.2 China Animal Husbandry Industry Reassortant Avian Influenza Virus Vaccine Product Portfolios and Specifications
13.6.3 China Animal Husbandry Industry Reassortant Avian Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 China Animal Husbandry Industry Main Business Overview
13.6.5 China Animal Husbandry Industry Latest Developments
13.7 Weike Biotechnology
13.7.1 Weike Biotechnology Company Information
13.7.2 Weike Biotechnology Reassortant Avian Influenza Virus Vaccine Product Portfolios and Specifications
13.7.3 Weike Biotechnology Reassortant Avian Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Weike Biotechnology Main Business Overview
13.7.5 Weike Biotechnology Latest Developments
13.8 Ringpu
13.8.1 Ringpu Company Information
13.8.2 Ringpu Reassortant Avian Influenza Virus Vaccine Product Portfolios and Specifications
13.8.3 Ringpu Reassortant Avian Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Ringpu Main Business Overview
13.8.5 Ringpu Latest Developments
13.9 Guangdong Winsun Bio Pharmaceutical
13.9.1 Guangdong Winsun Bio Pharmaceutical Company Information
13.9.2 Guangdong Winsun Bio Pharmaceutical Reassortant Avian Influenza Virus Vaccine Product Portfolios and Specifications
13.9.3 Guangdong Winsun Bio Pharmaceutical Reassortant Avian Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Guangdong Winsun Bio Pharmaceutical Main Business Overview
13.9.5 Guangdong Winsun Bio Pharmaceutical Latest Developments
13.10 Pulike
13.10.1 Pulike Company Information
13.10.2 Pulike Reassortant Avian Influenza Virus Vaccine Product Portfolios and Specifications
13.10.3 Pulike Reassortant Avian Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Pulike Main Business Overview
13.10.5 Pulike Latest Developments
13.11 QYH Biotech
13.11.1 QYH Biotech Company Information
13.11.2 QYH Biotech Reassortant Avian Influenza Virus Vaccine Product Portfolios and Specifications
13.11.3 QYH Biotech Reassortant Avian Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 QYH Biotech Main Business Overview
13.11.5 QYH Biotech Latest Developments
13.12 YEBIO Bioengineering
13.12.1 YEBIO Bioengineering Company Information
13.12.2 YEBIO Bioengineering Reassortant Avian Influenza Virus Vaccine Product Portfolios and Specifications
13.12.3 YEBIO Bioengineering Reassortant Avian Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 YEBIO Bioengineering Main Business Overview
13.12.5 YEBIO Bioengineering Latest Developments
13.13 Yikang Biological
13.13.1 Yikang Biological Company Information
13.13.2 Yikang Biological Reassortant Avian Influenza Virus Vaccine Product Portfolios and Specifications
13.13.3 Yikang Biological Reassortant Avian Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Yikang Biological Main Business Overview
13.13.5 Yikang Biological Latest Developments
13.14 DAHUANONG
13.14.1 DAHUANONG Company Information
13.14.2 DAHUANONG Reassortant Avian Influenza Virus Vaccine Product Portfolios and Specifications
13.14.3 DAHUANONG Reassortant Avian Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 DAHUANONG Main Business Overview
13.14.5 DAHUANONG Latest Developments
13.15 Guangzhou South China Biological Medicine
13.15.1 Guangzhou South China Biological Medicine Company Information
13.15.2 Guangzhou South China Biological Medicine Reassortant Avian Influenza Virus Vaccine Product Portfolios and Specifications
13.15.3 Guangzhou South China Biological Medicine Reassortant Avian Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Guangzhou South China Biological Medicine Main Business Overview
13.15.5 Guangzhou South China Biological Medicine Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. Reassortant Avian Influenza Virus Vaccine Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Reassortant Avian Influenza Virus Vaccine Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Bivalent Inactivated Vaccine
Table 4. Major Players of Trivalent Inactivated Vaccine
Table 5. Global Reassortant Avian Influenza Virus Vaccine Sales by Type (2018-2023) & (K Doses)
Table 6. Global Reassortant Avian Influenza Virus Vaccine Sales Market Share by Type (2018-2023)
Table 7. Global Reassortant Avian Influenza Virus Vaccine Revenue by Type (2018-2023) & ($ million)
Table 8. Global Reassortant Avian Influenza Virus Vaccine Revenue Market Share by Type (2018-2023)
Table 9. Global Reassortant Avian Influenza Virus Vaccine Sale Price by Type (2018-2023) & (US$/Dose)
Table 10. Global Reassortant Avian Influenza Virus Vaccine Sales by Application (2018-2023) & (K Doses)
Table 11. Global Reassortant Avian Influenza Virus Vaccine Sales Market Share by Application (2018-2023)
Table 12. Global Reassortant Avian Influenza Virus Vaccine Revenue by Application (2018-2023)
Table 13. Global Reassortant Avian Influenza Virus Vaccine Revenue Market Share by Application (2018-2023)
Table 14. Global Reassortant Avian Influenza Virus Vaccine Sale Price by Application (2018-2023) & (US$/Dose)
Table 15. Global Reassortant Avian Influenza Virus Vaccine Sales by Company (2018-2023) & (K Doses)
Table 16. Global Reassortant Avian Influenza Virus Vaccine Sales Market Share by Company (2018-2023)
Table 17. Global Reassortant Avian Influenza Virus Vaccine Revenue by Company (2018-2023) ($ Millions)
Table 18. Global Reassortant Avian Influenza Virus Vaccine Revenue Market Share by Company (2018-2023)
Table 19. Global Reassortant Avian Influenza Virus Vaccine Sale Price by Company (2018-2023) & (US$/Dose)
Table 20. Key Manufacturers Reassortant Avian Influenza Virus Vaccine Producing Area Distribution and Sales Area
Table 21. Players Reassortant Avian Influenza Virus Vaccine Products Offered
Table 22. Reassortant Avian Influenza Virus Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Reassortant Avian Influenza Virus Vaccine Sales by Geographic Region (2018-2023) & (K Doses)
Table 26. Global Reassortant Avian Influenza Virus Vaccine Sales Market Share Geographic Region (2018-2023)
Table 27. Global Reassortant Avian Influenza Virus Vaccine Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global Reassortant Avian Influenza Virus Vaccine Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global Reassortant Avian Influenza Virus Vaccine Sales by Country/Region (2018-2023) & (K Doses)
Table 30. Global Reassortant Avian Influenza Virus Vaccine Sales Market Share by Country/Region (2018-2023)
Table 31. Global Reassortant Avian Influenza Virus Vaccine Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global Reassortant Avian Influenza Virus Vaccine Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas Reassortant Avian Influenza Virus Vaccine Sales by Country (2018-2023) & (K Doses)
Table 34. Americas Reassortant Avian Influenza Virus Vaccine Sales Market Share by Country (2018-2023)
Table 35. Americas Reassortant Avian Influenza Virus Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas Reassortant Avian Influenza Virus Vaccine Revenue Market Share by Country (2018-2023)
Table 37. Americas Reassortant Avian Influenza Virus Vaccine Sales by Type (2018-2023) & (K Doses)
Table 38. Americas Reassortant Avian Influenza Virus Vaccine Sales by Application (2018-2023) & (K Doses)
Table 39. APAC Reassortant Avian Influenza Virus Vaccine Sales by Region (2018-2023) & (K Doses)
Table 40. APAC Reassortant Avian Influenza Virus Vaccine Sales Market Share by Region (2018-2023)
Table 41. APAC Reassortant Avian Influenza Virus Vaccine Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC Reassortant Avian Influenza Virus Vaccine Revenue Market Share by Region (2018-2023)
Table 43. APAC Reassortant Avian Influenza Virus Vaccine Sales by Type (2018-2023) & (K Doses)
Table 44. APAC Reassortant Avian Influenza Virus Vaccine Sales by Application (2018-2023) & (K Doses)
Table 45. Europe Reassortant Avian Influenza Virus Vaccine Sales by Country (2018-2023) & (K Doses)
Table 46. Europe Reassortant Avian Influenza Virus Vaccine Sales Market Share by Country (2018-2023)
Table 47. Europe Reassortant Avian Influenza Virus Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe Reassortant Avian Influenza Virus Vaccine Revenue Market Share by Country (2018-2023)
Table 49. Europe Reassortant Avian Influenza Virus Vaccine Sales by Type (2018-2023) & (K Doses)
Table 50. Europe Reassortant Avian Influenza Virus Vaccine Sales by Application (2018-2023) & (K Doses)
Table 51. Middle East & Africa Reassortant Avian Influenza Virus Vaccine Sales by Country (2018-2023) & (K Doses)
Table 52. Middle East & Africa Reassortant Avian Influenza Virus Vaccine Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa Reassortant Avian Influenza Virus Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa Reassortant Avian Influenza Virus Vaccine Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa Reassortant Avian Influenza Virus Vaccine Sales by Type (2018-2023) & (K Doses)
Table 56. Middle East & Africa Reassortant Avian Influenza Virus Vaccine Sales by Application (2018-2023) & (K Doses)
Table 57. Key Market Drivers & Growth Opportunities of Reassortant Avian Influenza Virus Vaccine
Table 58. Key Market Challenges & Risks of Reassortant Avian Influenza Virus Vaccine
Table 59. Key Industry Trends of Reassortant Avian Influenza Virus Vaccine
Table 60. Reassortant Avian Influenza Virus Vaccine Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Reassortant Avian Influenza Virus Vaccine Distributors List
Table 63. Reassortant Avian Influenza Virus Vaccine Customer List
Table 64. Global Reassortant Avian Influenza Virus Vaccine Sales Forecast by Region (2024-2029) & (K Doses)
Table 65. Global Reassortant Avian Influenza Virus Vaccine Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas Reassortant Avian Influenza Virus Vaccine Sales Forecast by Country (2024-2029) & (K Doses)
Table 67. Americas Reassortant Avian Influenza Virus Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC Reassortant Avian Influenza Virus Vaccine Sales Forecast by Region (2024-2029) & (K Doses)
Table 69. APAC Reassortant Avian Influenza Virus Vaccine Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe Reassortant Avian Influenza Virus Vaccine Sales Forecast by Country (2024-2029) & (K Doses)
Table 71. Europe Reassortant Avian Influenza Virus Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa Reassortant Avian Influenza Virus Vaccine Sales Forecast by Country (2024-2029) & (K Doses)
Table 73. Middle East & Africa Reassortant Avian Influenza Virus Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global Reassortant Avian Influenza Virus Vaccine Sales Forecast by Type (2024-2029) & (K Doses)
Table 75. Global Reassortant Avian Influenza Virus Vaccine Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 76. Global Reassortant Avian Influenza Virus Vaccine Sales Forecast by Application (2024-2029) & (K Doses)
Table 77. Global Reassortant Avian Influenza Virus Vaccine Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. Zoetis Basic Information, Reassortant Avian Influenza Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 79. Zoetis Reassortant Avian Influenza Virus Vaccine Product Portfolios and Specifications
Table 80. Zoetis Reassortant Avian Influenza Virus Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 81. Zoetis Main Business
Table 82. Zoetis Latest Developments
Table 83. Boehringer-Ingelheim Basic Information, Reassortant Avian Influenza Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 84. Boehringer-Ingelheim Reassortant Avian Influenza Virus Vaccine Product Portfolios and Specifications
Table 85. Boehringer-Ingelheim Reassortant Avian Influenza Virus Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 86. Boehringer-Ingelheim Main Business
Table 87. Boehringer-Ingelheim Latest Developments
Table 88. Eurovet Basic Information, Reassortant Avian Influenza Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 89. Eurovet Reassortant Avian Influenza Virus Vaccine Product Portfolios and Specifications
Table 90. Eurovet Reassortant Avian Influenza Virus Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 91. Eurovet Main Business
Table 92. Eurovet Latest Developments
Table 93. Merck Animal Health Basic Information, Reassortant Avian Influenza Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 94. Merck Animal Health Reassortant Avian Influenza Virus Vaccine Product Portfolios and Specifications
Table 95. Merck Animal Health Reassortant Avian Influenza Virus Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 96. Merck Animal Health Main Business
Table 97. Merck Animal Health Latest Developments
Table 98. BICR Basic Information, Reassortant Avian Influenza Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 99. BICR Reassortant Avian Influenza Virus Vaccine Product Portfolios and Specifications
Table 100. BICR Reassortant Avian Influenza Virus Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 101. BICR Main Business
Table 102. BICR Latest Developments
Table 103. China Animal Husbandry Industry Basic Information, Reassortant Avian Influenza Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 104. China Animal Husbandry Industry Reassortant Avian Influenza Virus Vaccine Product Portfolios and Specifications
Table 105. China Animal Husbandry Industry Reassortant Avian Influenza Virus Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 106. China Animal Husbandry Industry Main Business
Table 107. China Animal Husbandry Industry Latest Developments
Table 108. Weike Biotechnology Basic Information, Reassortant Avian Influenza Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 109. Weike Biotechnology Reassortant Avian Influenza Virus Vaccine Product Portfolios and Specifications
Table 110. Weike Biotechnology Reassortant Avian Influenza Virus Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 111. Weike Biotechnology Main Business
Table 112. Weike Biotechnology Latest Developments
Table 113. Ringpu Basic Information, Reassortant Avian Influenza Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 114. Ringpu Reassortant Avian Influenza Virus Vaccine Product Portfolios and Specifications
Table 115. Ringpu Reassortant Avian Influenza Virus Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 116. Ringpu Main Business
Table 117. Ringpu Latest Developments
Table 118. Guangdong Winsun Bio Pharmaceutical Basic Information, Reassortant Avian Influenza Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 119. Guangdong Winsun Bio Pharmaceutical Reassortant Avian Influenza Virus Vaccine Product Portfolios and Specifications
Table 120. Guangdong Winsun Bio Pharmaceutical Reassortant Avian Influenza Virus Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 121. Guangdong Winsun Bio Pharmaceutical Main Business
Table 122. Guangdong Winsun Bio Pharmaceutical Latest Developments
Table 123. Pulike Basic Information, Reassortant Avian Influenza Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 124. Pulike Reassortant Avian Influenza Virus Vaccine Product Portfolios and Specifications
Table 125. Pulike Reassortant Avian Influenza Virus Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 126. Pulike Main Business
Table 127. Pulike Latest Developments
Table 128. QYH Biotech Basic Information, Reassortant Avian Influenza Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 129. QYH Biotech Reassortant Avian Influenza Virus Vaccine Product Portfolios and Specifications
Table 130. QYH Biotech Reassortant Avian Influenza Virus Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 131. QYH Biotech Main Business
Table 132. QYH Biotech Latest Developments
Table 133. YEBIO Bioengineering Basic Information, Reassortant Avian Influenza Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 134. YEBIO Bioengineering Reassortant Avian Influenza Virus Vaccine Product Portfolios and Specifications
Table 135. YEBIO Bioengineering Reassortant Avian Influenza Virus Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 136. YEBIO Bioengineering Main Business
Table 137. YEBIO Bioengineering Latest Developments
Table 138. Yikang Biological Basic Information, Reassortant Avian Influenza Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 139. Yikang Biological Reassortant Avian Influenza Virus Vaccine Product Portfolios and Specifications
Table 140. Yikang Biological Reassortant Avian Influenza Virus Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 141. Yikang Biological Main Business
Table 142. Yikang Biological Latest Developments
Table 143. DAHUANONG Basic Information, Reassortant Avian Influenza Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 144. DAHUANONG Reassortant Avian Influenza Virus Vaccine Product Portfolios and Specifications
Table 145. DAHUANONG Reassortant Avian Influenza Virus Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 146. DAHUANONG Main Business
Table 147. DAHUANONG Latest Developments
Table 148. Guangzhou South China Biological Medicine Basic Information, Reassortant Avian Influenza Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 149. Guangzhou South China Biological Medicine Reassortant Avian Influenza Virus Vaccine Product Portfolios and Specifications
Table 150. Guangzhou South China Biological Medicine Reassortant Avian Influenza Virus Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 151. Guangzhou South China Biological Medicine Main Business
Table 152. Guangzhou South China Biological Medicine Latest Developments
List of Figures
Figure 1. Picture of Reassortant Avian Influenza Virus Vaccine
Figure 2. Reassortant Avian Influenza Virus Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Reassortant Avian Influenza Virus Vaccine Sales Growth Rate 2018-2029 (K Doses)
Figure 7. Global Reassortant Avian Influenza Virus Vaccine Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Reassortant Avian Influenza Virus Vaccine Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Bivalent Inactivated Vaccine
Figure 10. Product Picture of Trivalent Inactivated Vaccine
Figure 11. Global Reassortant Avian Influenza Virus Vaccine Sales Market Share by Type in 2022
Figure 12. Global Reassortant Avian Influenza Virus Vaccine Revenue Market Share by Type (2018-2023)
Figure 13. Reassortant Avian Influenza Virus Vaccine Consumed in Piglets
Figure 14. Global Reassortant Avian Influenza Virus Vaccine Market: Piglets (2018-2023) & (K Doses)
Figure 15. Reassortant Avian Influenza Virus Vaccine Consumed in Adults Pigs
Figure 16. Global Reassortant Avian Influenza Virus Vaccine Market: Adults Pigs (2018-2023) & (K Doses)
Figure 17. Global Reassortant Avian Influenza Virus Vaccine Sales Market Share by Application (2022)
Figure 18. Global Reassortant Avian Influenza Virus Vaccine Revenue Market Share by Application in 2022
Figure 19. Reassortant Avian Influenza Virus Vaccine Sales Market by Company in 2022 (K Doses)
Figure 20. Global Reassortant Avian Influenza Virus Vaccine Sales Market Share by Company in 2022
Figure 21. Reassortant Avian Influenza Virus Vaccine Revenue Market by Company in 2022 ($ Million)
Figure 22. Global Reassortant Avian Influenza Virus Vaccine Revenue Market Share by Company in 2022
Figure 23. Global Reassortant Avian Influenza Virus Vaccine Sales Market Share by Geographic Region (2018-2023)
Figure 24. Global Reassortant Avian Influenza Virus Vaccine Revenue Market Share by Geographic Region in 2022
Figure 25. Americas Reassortant Avian Influenza Virus Vaccine Sales 2018-2023 (K Doses)
Figure 26. Americas Reassortant Avian Influenza Virus Vaccine Revenue 2018-2023 ($ Millions)
Figure 27. APAC Reassortant Avian Influenza Virus Vaccine Sales 2018-2023 (K Doses)
Figure 28. APAC Reassortant Avian Influenza Virus Vaccine Revenue 2018-2023 ($ Millions)
Figure 29. Europe Reassortant Avian Influenza Virus Vaccine Sales 2018-2023 (K Doses)
Figure 30. Europe Reassortant Avian Influenza Virus Vaccine Revenue 2018-2023 ($ Millions)
Figure 31. Middle East & Africa Reassortant Avian Influenza Virus Vaccine Sales 2018-2023 (K Doses)
Figure 32. Middle East & Africa Reassortant Avian Influenza Virus Vaccine Revenue 2018-2023 ($ Millions)
Figure 33. Americas Reassortant Avian Influenza Virus Vaccine Sales Market Share by Country in 2022
Figure 34. Americas Reassortant Avian Influenza Virus Vaccine Revenue Market Share by Country in 2022
Figure 35. Americas Reassortant Avian Influenza Virus Vaccine Sales Market Share by Type (2018-2023)
Figure 36. Americas Reassortant Avian Influenza Virus Vaccine Sales Market Share by Application (2018-2023)
Figure 37. United States Reassortant Avian Influenza Virus Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 38. Canada Reassortant Avian Influenza Virus Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 39. Mexico Reassortant Avian Influenza Virus Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 40. Brazil Reassortant Avian Influenza Virus Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 41. APAC Reassortant Avian Influenza Virus Vaccine Sales Market Share by Region in 2022
Figure 42. APAC Reassortant Avian Influenza Virus Vaccine Revenue Market Share by Regions in 2022
Figure 43. APAC Reassortant Avian Influenza Virus Vaccine Sales Market Share by Type (2018-2023)
Figure 44. APAC Reassortant Avian Influenza Virus Vaccine Sales Market Share by Application (2018-2023)
Figure 45. China Reassortant Avian Influenza Virus Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 46. Japan Reassortant Avian Influenza Virus Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 47. South Korea Reassortant Avian Influenza Virus Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 48. Southeast Asia Reassortant Avian Influenza Virus Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 49. India Reassortant Avian Influenza Virus Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 50. Australia Reassortant Avian Influenza Virus Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 51. China Taiwan Reassortant Avian Influenza Virus Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 52. Europe Reassortant Avian Influenza Virus Vaccine Sales Market Share by Country in 2022
Figure 53. Europe Reassortant Avian Influenza Virus Vaccine Revenue Market Share by Country in 2022
Figure 54. Europe Reassortant Avian Influenza Virus Vaccine Sales Market Share by Type (2018-2023)
Figure 55. Europe Reassortant Avian Influenza Virus Vaccine Sales Market Share by Application (2018-2023)
Figure 56. Germany Reassortant Avian Influenza Virus Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 57. France Reassortant Avian Influenza Virus Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 58. UK Reassortant Avian Influenza Virus Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 59. Italy Reassortant Avian Influenza Virus Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 60. Russia Reassortant Avian Influenza Virus Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 61. Middle East & Africa Reassortant Avian Influenza Virus Vaccine Sales Market Share by Country in 2022
Figure 62. Middle East & Africa Reassortant Avian Influenza Virus Vaccine Revenue Market Share by Country in 2022
Figure 63. Middle East & Africa Reassortant Avian Influenza Virus Vaccine Sales Market Share by Type (2018-2023)
Figure 64. Middle East & Africa Reassortant Avian Influenza Virus Vaccine Sales Market Share by Application (2018-2023)
Figure 65. Egypt Reassortant Avian Influenza Virus Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 66. South Africa Reassortant Avian Influenza Virus Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 67. Israel Reassortant Avian Influenza Virus Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 68. Turkey Reassortant Avian Influenza Virus Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 69. GCC Country Reassortant Avian Influenza Virus Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 70. Manufacturing Cost Structure Analysis of Reassortant Avian Influenza Virus Vaccine in 2022
Figure 71. Manufacturing Process Analysis of Reassortant Avian Influenza Virus Vaccine
Figure 72. Industry Chain Structure of Reassortant Avian Influenza Virus Vaccine
Figure 73. Channels of Distribution
Figure 74. Global Reassortant Avian Influenza Virus Vaccine Sales Market Forecast by Region (2024-2029)
Figure 75. Global Reassortant Avian Influenza Virus Vaccine Revenue Market Share Forecast by Region (2024-2029)
Figure 76. Global Reassortant Avian Influenza Virus Vaccine Sales Market Share Forecast by Type (2024-2029)
Figure 77. Global Reassortant Avian Influenza Virus Vaccine Revenue Market Share Forecast by Type (2024-2029)
Figure 78. Global Reassortant Avian Influenza Virus Vaccine Sales Market Share Forecast by Application (2024-2029)
Figure 79. Global Reassortant Avian Influenza Virus Vaccine Revenue Market Share Forecast by Application (2024-2029)


★調査レポート[世界の再集合体鳥インフルエンザウイルスワクチン市場予測 2023年-2029年] (コード：LP23DC02948)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の再集合体鳥インフルエンザウイルスワクチン市場予測 2023年-2029年]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の吸入式鼻腔インフルエンザワクチン市場予測2023-2029：弱毒生インフルエンザワクチン、分割インフルエンザワクチン
  • 世界の吸入用組換え新型コロナウイルスワクチン市場予測 2023年-2029年
  • 世界の抗HCV（C型肝炎ウイルス）迅速検査キット（金コロイド法）市場予測 2023年-2029年
  • 世界のmRNA新型コロナウイルスワクチン市場予測 2023年-2029年
  • 世界のワクチン製造装置市場予測 2023年-2029年

    • ◆H&Iグローバルリサーチのお客様（例）◆